| Code | CSB-RA001950MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to aducanumab-avwa, targeting amyloid precursor protein (APP) and its cleavage products. APP is a transmembrane protein that undergoes sequential proteolytic processing to generate amyloid-beta (Aβ) peptides, which aggregate to form the characteristic amyloid plaques found in Alzheimer's disease. The accumulation of these Aβ aggregates, particularly soluble oligomers and insoluble fibrils, is central to the amyloid cascade hypothesis of neurodegeneration and represents a critical pathological hallmark of Alzheimer's disease.
Aducanumab-avwa is a human IgG1 monoclonal antibody that selectively targets aggregated forms of amyloid-beta, including soluble oligomers and insoluble fibrils, while showing minimal binding to monomeric Aβ. This biosimilar antibody provides researchers with a valuable tool for investigating amyloid pathology, studying the mechanisms of Aβ aggregation and clearance, and exploring therapeutic strategies for Alzheimer's disease. It enables studies of amyloid plaque formation, neuroinflammatory responses, and potential disease-modifying interventions in relevant experimental models.
There are currently no reviews for this product.